518 related articles for article (PubMed ID: 30306859)
1. Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation.
Athyros VG; Katsiki N; Dimakopoulou A; Patoulias D; Alataki S; Doumas M
Curr Pharm Des; 2018; 24(31):3638-3646. PubMed ID: 30306859
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
3. New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.
Su X; Peng DQ
Lipids Health Dis; 2018 Jan; 17(1):12. PubMed ID: 29334984
[TBL] [Abstract][Full Text] [Related]
4. Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia.
Papademetriou V; Stavropoulos K; Papadopoulos C; Koutsampasopoulos K; Dimitriadis K; Tsioufis K
Curr Pharm Des; 2018; 24(31):3647-3653. PubMed ID: 30317985
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
[TBL] [Abstract][Full Text] [Related]
6. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
7. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins.
Kim K; Ginsberg HN; Choi SH
Diabetes Metab J; 2022 Jul; 46(4):517-532. PubMed ID: 35929170
[TBL] [Abstract][Full Text] [Related]
8. PCSK9 Biology and Its Role in Atherothrombosis.
Barale C; Melchionda E; Morotti A; Russo I
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931
[TBL] [Abstract][Full Text] [Related]
9. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
Tziomalos K
Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
[TBL] [Abstract][Full Text] [Related]
10. Homozygous familial hypercholesterolemia: what treatments are on the horizon?
Bajaj A; Cuchel M
Curr Opin Lipidol; 2020 Jun; 31(3):119-124. PubMed ID: 32332430
[TBL] [Abstract][Full Text] [Related]
11. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
Auer J; Berent R
Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
[TBL] [Abstract][Full Text] [Related]
12. Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia.
Schmitz J; Gouni-Berthold I
Curr Pharm Des; 2017; 23(10):1484-1494. PubMed ID: 28137217
[TBL] [Abstract][Full Text] [Related]
13. New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?
Olkkonen VM; Sinisalo J; Jauhiainen M
Atherosclerosis; 2018 May; 272():27-32. PubMed ID: 29544086
[TBL] [Abstract][Full Text] [Related]
14. Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside.
Ling P; Zheng X; Luo S; Ge J; Xu S; Weng J
Diabetes Obes Metab; 2021 Sep; 23(9):2020-2034. PubMed ID: 34047441
[TBL] [Abstract][Full Text] [Related]
15. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
16. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
Michaeli DT; Michaeli JC; Albers S; Boch T; Michaeli T
Am J Cardiovasc Drugs; 2023 Sep; 23(5):477-495. PubMed ID: 37486464
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors.
Pirillo A; Catapano AL; Norata GD
Curr Atheroscler Rep; 2021 Oct; 23(12):79. PubMed ID: 34698927
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.
Peng W; Qiang F; Peng W; Qian Z; Ke Z; Yi L; Jian Z; Chongrong Q
Int J Cardiol; 2016 Nov; 222():119-129. PubMed ID: 27494723
[TBL] [Abstract][Full Text] [Related]
19. [PCSK9 inhibitors: What place in the management of dyslipidemia?].
Sabouret P; Farnier M; Puymirat E
Presse Med; 2019 Mar; 48(3 Pt 1):227-237. PubMed ID: 30853281
[TBL] [Abstract][Full Text] [Related]
20. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]